Benjamin F. Edwards & Company’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$0	Buy	1,150 +300	+35%	+$162	﹤0.01%	2227
2024 Q1	$1K	Hold	850	–	–	﹤0.01%	2091
2023 Q4	$0	Hold	850	–	–	﹤0.01%	2168
2023 Q3	$1K	Hold	850	–	–	﹤0.01%	1725
2023 Q2	$1K	Hold	850	–	–	﹤0.01%	1731
2023 Q1	$1K	Hold	850	–	–	﹤0.01%	1745
2022 Q4	$3K	Hold	850	–	–	﹤0.01%	1692
2022 Q3	$4K	Sell	850 -1,500	-64%	-$7.71K	﹤0.01%	1612
2022 Q2	$10K	Hold	2,350	–	–	﹤0.01%	1386
2022 Q1	$14K	Hold	2,350	–	–	﹤0.01%	1303
2021 Q4	$18K	Hold	2,350	–	–	﹤0.01%	1267
2021 Q3	$21K	Hold	2,350	–	–	﹤0.01%	1220
2021 Q2	$28K	Hold	2,350	–	–	﹤0.01%	1152
2021 Q1	$29K	Hold	2,350	–	–	﹤0.01%	1134
2020 Q4	$37K	Buy	2,350 +850	+57%	+$9.96K	﹤0.01%	1041
2020 Q3	$14K	Hold	1,500	–	–	﹤0.01%	1197
2020 Q2	$13K	Hold	1,500	–	–	﹤0.01%	1224
2020 Q1	$10K	Hold	1,500	–	–	﹤0.01%	1257
2019 Q4	$13K	Hold	1,500	–	–	﹤0.01%	1355
2019 Q3	$14K	Hold	1,500	–	–	﹤0.01%	1309
2019 Q2	$16K	Hold	1,500	–	–	﹤0.01%	1270
2019 Q1	$14K	Buy	+1,500	New	+$15.3K	﹤0.01%	1239

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Benjamin F. Edwards & Company's SGMO Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 35% in Q2 2024, buying an estimated $162 and bringing the position to 1,150 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

Benjamin F. Edwards & Company first reported a position in SGMO in Q1 2019 and has held it in 22 quarters since. The position peaked at $37K in Q4 2020. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

Benjamin F. Edwards & Company held 1,150 shares of SANGAMO THERAPEUTICS INC worth $0 as of Q2 2024.
Benjamin F. Edwards & Company bought 300 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $162.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2227 holding.
Benjamin F. Edwards & Company first reported a position in SANGAMO THERAPEUTICS INC in Q1 2019 and has held it in 22 quarters since.
Benjamin F. Edwards & Company's SANGAMO THERAPEUTICS INC position peaked at $37K in Q4 2020.
129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.